On Monday, Immuneering Corp (NASDAQ: IMRX) was -10.30% drop from the session before settling in for the closing price of $1.65. A 52-week range for IMRX has been $1.00 – $7.68.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -43.59% over the past five years. When this article was written, the company’s average yearly earnings per share was at 2.04%. With a float of $22.40 million, this company’s outstanding shares have now reached $31.05 million.
Let’s look at the performance matrix of the company that is accounted for 68 employees. In terms of profitability, gross margin is 100.58%, operating margin of 65.47%, and the pretax margin is 61.5%.
Immuneering Corp (IMRX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Immuneering Corp stocks. The insider ownership of Immuneering Corp is 27.87%, while institutional ownership is 13.87%. The most recent insider transaction that took place on Apr 01 ’24, was worth 1,160,181. In this transaction 10% Owner of this company sold 400,000 shares at a rate of $2.90, taking the stock ownership to the 2,895,273 shares. Before that another transaction happened on Mar 22 ’24, when Company’s Director bought 2,900 for $2.55, making the entire transaction worth $7,385. This insider now owns 2,900 shares in total.
Immuneering Corp (IMRX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.68 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.97% during the next five years compared to -57.97% drop over the previous five years of trading.
Immuneering Corp (NASDAQ: IMRX) Trading Performance Indicators
You can see what Immuneering Corp (IMRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.97, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of Immuneering Corp (IMRX)
Immuneering Corp (NASDAQ: IMRX) saw its 5-day average volume 0.24 million, a negative change from its year-to-date volume of 2.58 million. As of the previous 9 days, the stock’s Stochastic %D was 13.68%. Additionally, its Average True Range was 0.12.
During the past 100 days, Immuneering Corp’s (IMRX) raw stochastic average was set at 2.52%, which indicates a significant decrease from 12.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.88% in the past 14 days, which was lower than the 85.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9512, while its 200-day Moving Average is $1.7480. Nevertheless, the first resistance level for the watch stands at $1.6333 in the near term. At $1.7867, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8933. If the price goes on to break the first support level at $1.3733, it is likely to go to the next support level at $1.2667. Assuming the price breaks the second support level, the third support level stands at $1.1133.
Immuneering Corp (NASDAQ: IMRX) Key Stats
There are 31,050K outstanding shares of the company, which has a market capitalization of 45.95 million. As of now, sales total 0 K while income totals -53,470 K. Its latest quarter income was 0 K while its last quarter net income were -14,600 K.
